Publications by authors named "J L Asin"
Total sleep time (TST) misperception has been reported in obstructive sleep apnea (OSA). However, previous findings on predictors were inconsistent and predominantly relied on single-night polysomnography, which may alter patients' sleep perception. We leveraged advances in wearable sleep staging to investigate predictors of TST misperception in OSA over multiple nights in the home environment.
View Article and Find Full Text PDFPacific Coast tick fever is a recently described zoonotic disease in California caused by a spotted fever group rickettsia, Rickettsia rickettsii subsp. californica (formerly Rickettsia 364D) and transmitted by the Pacific Coast tick, Dermacentor occidentalis. Like many emerging vector-borne diseases, knowledge regarding the transmission cycle, contribution from potential amplifying hosts, and geographic distribution of R.
View Article and Find Full Text PDFArticle Synopsis
- - The study investigates the effectiveness of transvenous phrenic nerve stimulation (TPNS) as a treatment for central sleep apnea (CSA) in heart failure (HF) patients, who often have poor health outcomes related to CSA.
- - Researchers used a win ratio (WR) method to analyze data from a pivotal trial, comparing outcomes such as survival rates, hospitalization for heart failure, and patient-reported health status between those treated with TPNS and a control group.
- - Results indicate that TPNS significantly improves clinical outcomes for HF patients with CSA, showing a higher number of positive outcomes for those receiving treatment compared to the control group.
Article Synopsis
- * The panel emphasized the need for improved diagnostic methods, including multi-night assessments and new metrics to differentiate CSA from obstructive sleep apnea, which could enhance treatment outcomes.
- * Future research should investigate the effects of CSA on patients, optimize therapeutic approaches, and explore new diagnostic techniques and combination therapies for effective CSA management.
Article Synopsis
- Obstructive sleep apnea (OSA) often causes excessive daytime sleepiness (EDS), and pitolisant, a medication that targets histamine receptors, was tested for its efficacy in treating this issue in patients with moderate to severe OSA.
- In a clinical trial with 361 participants, pitolisant was administered in varying doses up to 40 mg daily for 12 weeks, showing a significant reduction in EDS as measured by the Epworth Sleepiness Scale compared to a placebo.
- The study found that pitolisant was well tolerated and improved not only daytime sleepiness but also reaction times and overall patient satisfaction, regardless of whether patients used continuous positive airway pressure (CPAP) therapy.